BioSpace News Archive

Palatin Technologies, Inc today announced the publication of a third-party clinical study with bremelanotide (Vyleesi) in the Journal of Clinical Investigation entitled “Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder,” by Thurston, et al. (Reference: J Clin Invest. 2022;132(19):e152341.

Qu Biologics Inc. is pleased to announce that it is receiving advisory services and research and development funding of up to $6,659,050 from the National Research Council of Canada Industrial Research Assistance Program to support the implementation and completion of a Phase II randomized, placebo-controlled clinical trial of QBKPN SSI, a first-in-class immune modulator designed to optimize immunity and barrier function in the lungs.

RLDatix, the leading global provider of healthcare operations software and services that drive safer care, announced today that it has entered into a definitive agreement to acquire Porzio Life Sciences.

Takara Bio USA, Inc., a pioneering life science reagent and instrument company and wholly owned subsidiary of Takara Bio Inc., is partnering with BioExcel Diagnostics to develop and validate a new high-throughput and comprehensive method for detecting syndromic-based infectious diseases.

Ankyra Therapeutics, a company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Joseph J. Elassal, M.D., as chief medical officer.

Arrivo BioVentures today announced preliminary results from its SP-624-201 study, a randomized, placebo-controlled Phase 2 clinical trial of SP-624 in 319 patients with major depressive disorder (MDD).

Revance Therapeutics, Inc. today announced the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer to lead clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs.

Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.

CEL-SCI Corporation (NYSE American: CVM) today announced the availability to the public of an oral presentation delivered by Dr. Philip Lavin of groundbreaking tumor response and increased overall survival in head and neck cancer.